Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant (RLI)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Bimalangshu Dey, Massachusetts General Hospital
Information provided by (Responsible Party):
Bimalangshu Dey, Massachusetts General Hospital Identifier:
First received: May 27, 2009
Last updated: February 27, 2017
Last verified: February 2017

The proposed study is based on our observation of paradoxical tumor regression after rejection of the donor graft in conjunction with the results of our murine experiments. We hypothesize that clinically meaningful responses can be achieved in patients with advanced malignancies with a transplant strategy using nonmyeloablative conditioning and related mismatched donor stem cell transplant where the intention will be to initially achieve mixed chimerism which will be followed by recipient lymphocyte infusion (RLI) in an attempt to deliberately reject the donor graft. This will lead to the development of novel transplant strategies for achieving antitumor effects without the risk of graft versus host disease (GVHD). This proposed protocol is a Pilot Study that will evaluate the safety of this outpatient transplant strategy, i.e., establishment of initial mixed chimerism followed by RLI for donor graft rejection, in patients with advanced lymphomas, and multiple myeloma.

In addition, because RLI have been reported to reverse ongoing GVHD, this approach might potentially reverse GVHD while achieving antitumor responses if this complication unexpectedly occurs.

Condition Intervention Phase
Non Hodgkin's Lymphoma
Hodgkin Disease
Multiple Myeloma
Other: Fludarabine and total body irradiation
Radiation: Total body irradiation
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant

Resource links provided by NLM:

Further study details as provided by Bimalangshu Dey, Massachusetts General Hospital:

Primary Outcome Measures:
  • To determine the safety at ≤100 days of a non myeloablative mismatched related HCT when followed by recipient leukocyte infusion to induce deliberate rejection of the donor graft. [ Time Frame: 100 days post transplant ]

Secondary Outcome Measures:
  • To evaluate the incidence of acute and chronic GVHD [ Time Frame: Up to 2 years post transplant ]
  • To evaluate the incidence of loss of donor grafts [ Time Frame: Up to 2 years post transplant ]
  • To evaluate progression-free and overall survival [ Time Frame: Up to 2 years post transplant ]
  • To evaluate antitumor responses following this transplant strategy [ Time Frame: Up to 2 years post transplant ]

Estimated Enrollment: 20
Study Start Date: November 2008
Estimated Study Completion Date: November 2018
Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fludarabine
The patients in this cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
Other: Fludarabine and total body irradiation
The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
Active Comparator: TBI only
Patients will be given 200 centiGray (cGy) total body irradiation (TBI) in one fraction. TBI will be given on day 0, 4 to 6 hours prior to HCT.
Radiation: Total body irradiation
Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with chemorefractory non-Hodgkin's or Hodgkin's lymphoma or multiple myeloma.

    Criteria for consideration of enrollment will include:

    1. primary refractory or refractory relapsed disease for which autologous HCT is unlikely to be beneficial;
    2. relapse after autologous HCT
    3. ineligibility for standard myeloablative or nonmyeloablative allo-HCT because of either lack of a donor or patient considerations
  2. Non Hodgkin's lymphoma, or Hodgkin's lymphoma: primary refractory or refractory relapse
  3. Multiple myeloma; primary refractory or refractory relapse
  4. Patients with the above malignancies who have had a previous autologous or allogeneic bone marrow or stem cell transplant.
  5. An estimated disease-free survival of less than one year.
  6. Age 18 to age < 75 years
  7. ECOG performance status of 0, 1, or 2.

Exclusion Criteria:

  1. Patients whose life expectancy is limited by diseases other than their malignancy
  2. Patients who have a 5/6 or better matched related donor or a 4/6 or better umbilical cord blood donor and who are medically eligible for conventional myeloablative or non-myeloablative transplant will be excluded
  3. Cardiac disease: symptomatic congestive heart failure or RVG or echocardiogram determined LVEF ogf< 30%, active angina pectoris or uncontrolled hypertension
  4. Pulmonary disease: severe chronic obstructive lung disease, or symptomatic restrictive lung disease, or corrected DLCO < 40% of predicted
  5. Renal disease: serum creatinine > 3.0 mg/dl.
  6. Hepatic disease: serum bilirubin > 3.0 mg/dl or alkaline phosphatase, SGOT or SGPT > 3 x ULN
  7. Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation (pervious CNS malignancy presently in CR is not an exclusion)
  8. Uncontrolled infection.
  9. Recipient leukocyte infusion (RLI) might involve the infusion of circulating tumor cells to the patients. To minimize this risk patients who have evidence of circulating tumor cells by light microscopy and flow cytometry will be excluded
  10. Patients with acute leukemia will be excluded because they will likely have much greater circulating tumor burden, which would increase the risk of infusion of clonal tumor cells
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00909948

Contact: Bimalangshu R Dey, MD, PhD 617-724-5255

United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Bimalangshu R Dey, MD, PhD    617-724-5255   
Sub-Investigator: Thomas R Spitzer, MD         
Sub-Investigator: Steven L McAfee, MD         
Sub-Investigator: Karen Ballen, MD         
Sub-Investigator: Eyal Attar, MD         
Sub-Investigator: Yi-Bin Chen, MD         
Sub-Investigator: Megan Sykes, MD         
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Bimalangshu R Dey, MD, PhD MGH
  More Information


Responsible Party: Bimalangshu Dey, MD, Massachusetts General Hospital Identifier: NCT00909948     History of Changes
Obsolete Identifiers: NCT00981760
Other Study ID Numbers: Protocol 07-068
Study First Received: May 27, 2009
Last Updated: February 27, 2017

Keywords provided by Bimalangshu Dey, Massachusetts General Hospital:
Related stem cell transplant,
Mismatched stem cell transplant
Multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Lymphoma, Non-Hodgkin
Hodgkin Disease
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Lymphatic Diseases
Fludarabine phosphate
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents processed this record on May 25, 2017